Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?

  • P De Vos*
  • , JFM Van Straaten
  • , AG Nieuwenhuizen
  • , M de Groot
  • , RJ Ploeg
  • , PJ De Haan
  • , R Van Schilfgaarde
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

189 Citations (Scopus)

Abstract

The survival of microencapsulated islet grafts is Limited, even if capsular overgrowth is restricted to a small percentage of the capsules. In search of processes other than overgrowth contributing to graft failure, we have studied the islets in non-overgrown capsules at several time points after allotransplantation in the rat. All recipients of islet allografts became normoglycemic. Grafts were retrieved at 4 and 8 weeks after implantation and at 15.3 +/- 2.3 weeks postimplant, 2 weeks after the mean time period at which graft failure occurred. Overgrowth of capsules was complete within 4 weeks postimplant, and it was usually restricted to

Original languageEnglish
Pages (from-to)1381-1388
Number of pages8
JournalDiabetes
Volume48
Issue number7
Publication statusPublished - Jul-1999

Keywords

  • BETA-CELL MASS
  • ALGINATE-POLYLYSINE MICROCAPSULES
  • RAT PANCREATIC-ISLETS
  • DIABETIC NUDE-MICE
  • BIOARTIFICIAL PANCREAS
  • GLUCOSE-INFUSION
  • INSULIN RELEASE
  • TRANSPLANTATION
  • GROWTH
  • BIOCOMPATIBILITY

Fingerprint

Dive into the research topics of 'Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?'. Together they form a unique fingerprint.

Cite this